REGN Analyst Ratings
Regeneron Pharmaceuticals, Inc. (REGN) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $98.82B, listed on NASDAQ, employing roughly 15,410 people, carrying a beta of 0.24 to the broader market. Regeneron Pharmaceuticals, Inc. Led by Leonard S. Schleifer, public since 1991-04-02.
Analyst Ratings
In the November 2026 monthly count, 29 analysts rated REGN: 4 Strong Buy, 15 Buy, 9 Hold, 0 Sell and 1 Strong Sell.
Twelve months earlier, in November 2025: 29 analysts, 4 Strong Buy, 16 Buy, 8 Hold, 0 Sell and 1 Strong Sell.
Price Targets
- Average Target
- $904.60
- Median Target
- $875.00
- High
- $1100.00
- Low
- $756.00
- Targets Published, Last 12 Months
- 71
Recent Price Targets
The 5 most recent of 71 price targets published in the last 12 months.
| Date | Firm | Analyst | Target | Price When Posted |
|---|---|---|---|---|
| Nov 11, 2026 | Jefferies | Akash Tewari | $1,065.00 | $946.47 |
| Nov 2, 2026 | Cantor Fitzgerald | Carter Gould | $980.00 | $962.36 |
| Nov 2, 2026 | Wells Fargo | Not named | $1,030.00 | $927.89 |
| Nov 2, 2026 | Guggenheim | Yatin Suneja | $1,100.00 | $927.89 |
| Nov 2, 2026 | Wells Fargo | Mohit Bansal | $925.00 | $927.89 |
Recent Upgrades & Downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | Bernstein | maintain | Market Perform | Market Perform |
| Nov 2, 2026 | Leerink Partners | maintain | Market Perform | Market Perform |
| Nov 2, 2026 | B of A Securities | maintain | Buy | Buy |
| Nov 2, 2026 | Baird | maintain | Neutral | Neutral |
| Nov 2, 2026 | Cantor Fitzgerald | maintain | Overweight | Overweight |
Quantitative Rating
REGN carries a model grade of A (overall score 4 of 5), computed from six valuation and financial measures (discounted cash flow, return on equity, return on assets, debt to equity, price to earnings and price to book), each scored 1 to 5. It is not an analyst rating.
How to Read REGN Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →
Frequently asked REGN analyst ratings questions
- What is the REGN consensus price target?
- As of the latest aggregator update, Regeneron Pharmaceuticals, Inc. (REGN) carries a consensus 12-month price target of $904.60. Target ranges run from a low of $756.00 to a high of $1100.00. The target is the average of the price targets published by sell-side equity analysts covering the name.
- What is the analyst rating consensus on REGN?
- In the November 2026 monthly count, 29 analysts rated REGN, and the distribution tilts to the Buy side: 4 Strong Buy, 15 Buy, 9 Hold, 0 Sell and 1 Strong Sell. Rating consensus moves slowly relative to price; it reflects sell-side conviction over a 12-month horizon rather than near-term momentum.
- What recent ratings actions has REGN seen?
- The five most recent ratings actions on REGN appear on the page above. Sell-side rating changes are watched for two reasons: an upgrade or downgrade with a meaningful target revision moves the consensus and can trigger short-term positioning shifts, and the firm-level rating cluster (multiple firms moving in the same direction within a short window) is a clearer signal than any single action. Options markets often price the implied-vol response within minutes of the announcement.
- How do analyst targets affect REGN options pricing?
- Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.